Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21883159 | 0.88 | EGFR (0.54) | MAPTGAAHPGDNPC1LMNA | |
| SCHEMBL32665830 | 0.85 | NPC1 (0.51) | MAPTGAAHPGDNPC1LMNA | |
| SCHEMBL21883132 | 0.85 | NPC1 (0.51) | MAPTGAAHPGDNPC1LMNA | |
| SCHEMBL24221964 | 0.84 | SMN1; SMN2 (0.47) | MAPTGAAHPGDNPC1LMNA | |
| SCHEMBL21883161 | 0.80 | KMT2A (0.51) | MAPTHPGDNPC1LMNAALOX15 | |
| SCHEMBL21883512 | 0.77 | PLAU (0.48) | MAPTGAANPC1LMNAKMT2A | |
| SCHEMBL21883139 | 0.75 | SMN1; SMN2 (0.47) | MAPTGAANPC1LMNARAB9A | |
| SCHEMBL21883160 | 0.74 | POLB (0.55) | MAPTHPGDNPC1LMNARAB9A | |
| SCHEMBL32665832 | 0.74 | POLB (0.55) | MAPTHPGDNPC1LMNARAB9A | |
| SCHEMBL21883129 | 0.74 | MEN1 (0.46) | MAPTGAANPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12534440-B2 | Compounds with copper- or zinc-activated toxicity against microbial infection | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2026-01-27 | — | — | US | disclosed |
| US-20220024877-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | THE UAB RESEARCH FOUNDATION | 2022-01-27 | — | — | US | disclosed |
| WO-2020061412-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061412-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534440-B2 | Compounds with copper- or zinc-activated toxicity against microbial infection | TST, SLC39A11, SLC39A3 | MAPT 1521/4885GAA 2353/4885HPGD 2107/4885 |
| US-20220024877-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | SLC39A11, CNBP, SLC39A3 | MAPT 2375/4885GAA 2388/4885HPGD 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.